Chembio Diagnostics to Report Second Quarter 2019 Financial Results on August 6, 2019

NEXT STORY
Study Published in American Health Drug Benefits Suggests that Non-Invasive Screening Methods, Including Epi proColon®, Could Be A Cost-Effective Option To Help Achieve Target U.S. Colorectal Cancer Screening Rates
PREV STORY
Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Argos Therapeutics to Participate in 2016 EORTC-AACR-NCI Symposium

DURHAM, N.C., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an ...

author_avatar
NASDAQ Market News

Bavarian Nordic to Present at Jefferies 2017 Healthcare Conference in New York

COPENHAGEN, Denmark - June 1, 2017 - Bavarian Nordic A/S (OMX:  BAVA, OTC: BVNRY) ...

author_avatar
NASDAQ Market News

Aptevo Therapeutics Completes Sale of Hyperimmune Products for Up to $74.5 Million

Sharpens Focus on Innovative ADAPTIR® Bispecific Antibody Platform and IXINITY® Commercial Asset Strengthens Cash Position ...

author_avatar
NASDAQ Market News